Core Insights - I-Mab has announced a new business model aimed at accelerating access to innovative medicines and enabling strategic growth, including plans for a dual listing on NASDAQ and the Hong Kong Stock Exchange (HKEX) under the new name NovaBridge Biosciences [1][6][18] Business Model and Strategy - The new business model reflects a strategic transition to a global biotech platform focused on business development and translational clinical development [6] - The company intends to utilize a "hub-and-spoke" model to create specialized subsidiary companies, allowing for optimal risk management and value creation [8] - I-Mab aims to partner with leading innovators to identify and accelerate high-value assets, leveraging insights from the CBC Group to develop promising drug candidates [7][5] Financial and Leadership Changes - Kyler Lei has been appointed as Chief Financial Officer, bringing extensive experience in global capital markets and healthcare [13][14] - The company has secured additional capital and attracted seasoned biotech executives to its Board of Directors and Scientific Advisory Board [7] Acquisition and Pipeline Developments - I-Mab is in the process of acquiring VIS-101, a bifunctional biologic targeting VEGF-A and ANG2, which is expected to provide more durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) [2][10] - The acquisition will be completed by a newly formed subsidiary, Visara, which will focus on developing ophthalmic therapeutics [10][21] - The pipeline includes givastomig, a potential best-in-class therapy for gastric cancer, with a global Phase 2 study expected to begin in Q1 2026 [11][19] Market Potential and Growth Opportunities - The Asia Pacific region has generated over 30% of global biopharma assets under development and achieved more than $80 billion in deal value through collaborations with multinational pharmaceutical organizations [4] - The biopharmaceutical ecosystem in Asia Pacific is becoming increasingly efficient, with lower clinical trial costs and faster patient enrollment compared to global medians [4]